Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation

BackgroundAcquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) inevitably occurs in non-small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations. There are approximately half of the patients who developed resistance to EGFR-TKIs treatment,...

Full description

Bibliographic Details
Main Authors:	Jianxin Chen, Xilin Wu, Junhui Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Oncology
Subjects:	icotinib double dose T790M mutation lung cancer epidermal growth factor receptor
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.898586/full

Similar Items

Clinical Analysis of Icotinib on Beneficiary of  Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
by: Xiaowen JIANG, et al.
Published: (2016-04-01)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
by: Junhui Wang, et al.
Published: (2019-02-01)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
by: Akihiro Yoshimura, et al.
Published: (2018-12-01)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
by: Wang L, et al.
Published: (2021-03-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
by: Ikei S. Kobayashi, MD, PhD, et al.
Published: (2024-01-01)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
by: Hardy Niu, et al.
Published: (2017-09-01)

Exhaled breath condensate confirming T790M mutation in EGFR-mutated Non-Small Cell Lung Cancer
by: Caitriona Goggin, et al.
Published: (2021-12-01)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
by: Gao X, et al.
Published: (2019-11-01)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
by: Kana Watanabe, et al.
Published: (2023-08-01)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
by: Liu YT, et al.
Published: (2020-06-01)

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
by: Zhansheng Jiang, et al.
Published: (2021-09-01)

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs
by: Zheng Wang, et al.
Published: (2021-05-01)

EGFR T790M: revealing the secrets of a gatekeeper
by: Ko B, et al.
Published: (2017-10-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trialResearch in context
by: Wei Ou, et al.
Published: (2023-03-01)

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
by: Xiao-Fang Yi, et al.
Published: (2022-06-01)

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR
by: Faisal A. Almalki, et al.
Published: (2021-10-01)

Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
by: Muhammad Harbi Praditya, et al.
Published: (2023-01-01)

Droplet Digital PCR as a Molecular Tool for the Detection of the EGFR T790M Mutation in NSCLC Patients with the EGFR Activating Mutations
by: Durgut S, et al.
Published: (2024-03-01)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
by: Yang Chen, et al.
Published: (2018-03-01)

Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
by: Xue YANG, et al.
Published: (2022-05-01)

Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer
by: HOU Ran, et al.
Published: (2020-06-01)

Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
by: Asao Sakai, et al.
Published: (2013-01-01)

Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
by: Olivia A. Sagan, et al.
Published: (2023-05-01)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
by: Asim Joshi, et al.
Published: (2022-08-01)

Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations
by: Hongyue Qin, et al.
Published: (2022-09-01)

The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer
by: Wen-Chien Cheng, et al.
Published: (2022-12-01)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01)

Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations
by: Huaxin Zhou, et al.
Published: (2022-05-01)

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2022-10-01)

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
by: Shinichi Miyazaki, et al.
Published: (2020-08-01)

Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
by: Minehiko Inomata, et al.
Published: (2020-11-01)

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion
by: Lanzi Ou, et al.
Published: (2022-07-01)

Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy
by: Martin Filipits, et al.
Published: (2023-07-01)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
by: Yan Chen, et al.
Published: (2022-06-01)

Comparative analysis of QS3D versus droplet digital PCR for quantitative measures of EGFR T790M mutation from identical plasma
by: Qiaomei Guo, et al.
Published: (2022-11-01)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
by: Naoki Haratake, MD, PhD, et al.
Published: (2020-11-01)

Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
by: Yoshiya Matsumoto, et al.
Published: (2022-07-01)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
by: Akihiro Yoshimura, et al.
Published: (2019-03-01)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
by: Qiufan Zheng, et al.
Published: (2020-02-01)